Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Total Non-Current Liabilities (2023 - 2024)

Alto Neuroscience has reported Total Non-Current Liabilities over the past 2 years, most recently at $26.1 million for Q4 2024.

  • Quarterly results put Total Non-Current Liabilities at $26.1 million for Q4 2024, up 68.59% from a year ago — trailing twelve months through Dec 2024 was $26.1 million (up 68.59% YoY), and the annual figure for FY2024 was $26.1 million, up 68.59%.
  • Total Non-Current Liabilities reached $26.1 million in Q4 2024 per ANRO's latest filing, down from $26.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $59.7 million in Q3 2023 and bottomed at $15.5 million in Q4 2023.